BRIM Biotechnology, Inc.

As of June 30, 2026, BRIM Biotechnology, Inc. carries a market capitalization of 2.84B, placing it among publicly traded companies globally. Its enterprise value stands at 1.95B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BRIM Biotechnology, Inc.'s next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2026, BRIM Biotechnology, Inc. has 133.02M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 266.64, and the price-to-book ratio stands at 1.84.

These figures are as of June 30, 2026. The EV/Sales ratio of 183.53 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.95B versus a market cap of 2.84B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, BRIM Biotechnology, Inc. maintains a current ratio of 27.96, meaning it holds 28.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.63, indicating moderate leverage, while an interest coverage ratio of -720.91 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, BRIM Biotechnology, Inc. posted a negative return on equity (ROE) of -25.03, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -22.12, reflecting losses generated across the asset base. The company generates approximately 441,833.33 in revenue per employee across its workforce of 24.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, BRIM Biotechnology, Inc. recorded 33,000.00 in income tax expense. The company reported a pretax loss of -463.63M and -428.00M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, BRIM Biotechnology, Inc.'s stock has declined approximately 7.49% over the past 52 weeks. The 50-day moving average sits at 26.62, while the 200-day moving average is 24.88.

Over the twelve months ended June 30, 2026, BRIM Biotechnology, Inc. generated 10.60M in revenue and converted that into -428.00M in net income, yielding earnings per share of -3.50. EBITDA reached -412.36M, while operating income came in at -459.94M.

As of June 30, 2026, BRIM Biotechnology, Inc. holds 981.50M in cash and equivalents against 10.28M in total debt, resulting in a net debt position of -291.17M. Total book value stands at 1.54B, with working capital of 1.01B providing operational flexibility.

BRIM Biotechnology, Inc. produced -334.44M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -326.52M in capital expenditures, free cash flow totaled -660.95M - equivalent to -4.99 per share.

Over the twelve months ended June 30, 2026, BRIM Biotechnology, Inc. posted a gross margin of -13.32, reflecting its pricing power and cost economics. The operating margin of -4,337.40 and net profit margin of -4,036.18 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -23.38: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.94, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to BRIM Biotechnology, Inc. shareholders.

BRIM Biotechnology, Inc.'s most recent stock split took place on July 17, 2023.

As of June 30, 2026, BRIM Biotechnology, Inc. has an Altman Z-Score of 38.45, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.